A dose-response study in mice of a tetravalent recombinant dengue envelope domain III protein secreted from insect cells

被引：0

作者：

Shao, Lijun ^{[1
]}

Pang, Zheng ^{[2
]}

Bi, Yu ^{[1
]}

Li, Zhenhua ^{[1
]}

Lin, Weiping ^{[1
]}

Li, Guolei ^{[1
]}

Guo, Yanming ^{[1
]}

Qi, Jun ^{[3
]}

Niu, Guoyu ^{[1
]}

机构：

[1] WeiFang Med Univ, Sch Publ Hlth, Key Lab Hlth Inspect & Quarantine Weifang, Weifang 261053, Peoples R China

[2] Tianjin Int Joint Acad Biomed, Tianjin 300457, Peoples R China

[3] Tianjin Int Travel Healthcare Ctr, Tianjin Customs Port Out Patient Dept, Tianjin 300456, Peoples R China

来源：

INFECTION GENETICS AND EVOLUTION | 2020年 / 85卷

关键词：

Dengue virus; Tetravalent; Humoral immunity; Cellular immunity; Vaccine; ANTIBODY-DEPENDENT ENHANCEMENT; VIRUS SEROTYPE-1; PROTECTIVE ROLE; VACCINE; INFECTION; IMMUNOGENICITY; GLYCOPROTEIN; EFFICACY; IMMUNITY; PHASE;

D O I：

10.1016/j.meegid.2020.104427

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: DENV is the most globally prevalent mosquito-transmitted virus. Induction of a broadly and potently immune response is desirable for dengue vaccine development. Methods: Several formulations of secreted tetravalent EDIII protein containing different amounts of antigen from eukaryotic cells were used to evaluate the immune responses in mice. Results: We demonstrated that the tetravalent protein induced humoral immunity against all four serotypes of DENV, even at the lowest dose assayed. Besides, cellular immunities against DENV-1 and DENV-2 were elicited by medium dose group. Importantly, the immune responses induced by the tetravalent protein were functional in clearing DENV-2 in circulation of mice. Conclusions: We believe that the tetravalent secreted EDIII protein is a potential vaccine candidate against DENV and suggest further detailed studies of this formulation in nonhuman primates.

引用

页数：8

共 55 条

[1] The risks behind Dengvaxia recommendation [J].

Aguiar, Maira ;

Stollenwerk, Nico ;

Halstead, Scott B. .

LANCET INFECTIOUS DISEASES, 2016, 16 (08) :882-883

[2] Dengue vaccine: reliably determining previous exposure [J].

Arien, Kevin K. ;

Wilder-Smith, Annelies .

LANCET GLOBAL HEALTH, 2018, 6 (08) :E830-E831

[3] The global distribution and burden of dengue [J].

Bhatt, Samir ;

Gething, Peter W. ;

Brady, Oliver J. ;

Messina, Jane P. ;

Farlow, Andrew W. ;

Moyes, Catherine L. ;

Drake, John M. ;

Brownstein, John S. ;

Hoen, Anne G. ;

Sankoh, Osman ;

Myers, Monica F. ;

George, Dylan B. ;

Jaenisch, Thomas ;

Wint, G. R. William ;

Simmons, Cameron P. ;

Scott, Thomas W. ;

Farrar, Jeremy J. ;

Hay, Simon I. .

NATURE, 2013, 496 (7446) :504-507

[4] A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice [J].

Block, Olivia K. T. ;

Rodrigo, W. W. Shanaka I. ;

Quinn, Matthew ;

Jin, Xia ;

Rose, Robert C. ;

Schlesinger, Jacob J. .

VACCINE, 2010, 28 (51) :8085-8094

[5] Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial [J].

Capeding, Maria Rosario ;

Ngoc Huu Tran ;

Hadinegoro, Sri Rezeki S. ;

Ismail, Hussain Imam H. J. Muhammad ;

Chotpitayasunondh, Tawee ;

Chua, Mary Noreen ;

Chan Quang Luong ;

Rusmil, Kusnandi ;

Wirawan, Dewa Nyoman ;

Nallusamy, Revathy ;

Pitisuttithum, Punnee ;

Thisyakorn, Usa ;

Yoon, In-Kyu ;

van der Vliet, Diane ;

Langevin, Edith ;

Laot, Thelma ;

Hutagalung, Yanee ;

Frago, Carina ;

Boaz, Mark ;

Wartel, T. Anh ;

Tornieporth, Nadia G. ;

Saville, Melanie ;

Bouckenooghe, Alain .

LANCET, 2014, 384 (9951) :1358-1365

[6] Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein [J].

Chen, Shuiping ;

Yu, Man ;

Jiang, Tao ;

Deng, Yongqiang ;

Qin, Chengfeng ;

Qin, Ede .

DNA AND CELL BIOLOGY, 2007, 26 (06) :361-367

[7] Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice [J].

Chiang, Chen-Yi ;

Pan, Chien-Hsiung ;

Chen, Mei-Yu ;

Hsieh, Chun-Hsiang ;

Tsai, Jy-Ping ;

Liu, Hsueh-Hung ;

Liu, Shih-Jen ;

Chong, Pele ;

Leng, Chih-Hsiang ;

Chen, Hsin-Wei .

SCIENTIFIC REPORTS, 2016, 6

[8] The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry [J].

Chin, J. F. L. ;

Chu, J. J. H. ;

Ng, M. L. .

MICROBES AND INFECTION, 2007, 9 (01) :1-6

[9] Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies [J].

Coudeville, Laurent ;

Baurin, Nicolas ;

Vergu, Elisabeta .

VACCINE, 2016, 34 (50) :6417-6425

[10] Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells [J].

Crill, WD ;

Roehrig, JT .

JOURNAL OF VIROLOGY, 2001, 75 (16) :7769-7773

← 1 2 3 4 5 6 →